ESMO Asia 2020: Anlotinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
Posted: Monday, December 7, 2020
Yihebali Chi, MD, PhD, of the National Cancer Center, Beijing, and colleagues, established that there was a notable progression-free survival benefit when patients with metastatic or locally advanced radioiodine-refractory differentiated thyroid carcinoma were treated with anlotinib versus a placebo. Greater response rates were also demonstrated with this multikinase inhibitor, and the study findings were presented at the European Society for Medical Oncology (ESMO) Asia Virtual Congress 2020 (Abstract 265O).
This phase II, double-blind, multicenter study enrolled a total of 113 patients. All participants had pathologically confirmed, measurable radioiodine-refractory differentiated thyroid carcinoma. Patients were randomly placed 2:1 into treatment arms. The first group consisted of 76 participants treated with 12 mg daily of anlotinib for 2 weeks, followed by a week of rest; the other group consisted of 37 participants who were administered a placebo with the same regimen. Upon disease progression, patients on the placebo arm were permitted to cross over to open-label anlotinib.
At the time of data cutoff, the median progression-free survival was 40.5 months with anlotinib, whereas it was 8.38 months with placebo. The participants administered anlotinib had an objective response rate of 59.21%, compared with no response for those who received a placebo.
Adverse events occurred in 100% and 97.30% of the anlotinib and placebo groups, respectively; the prevalence of treatment-related adverse events was 100% and 86.49%, respectively. Hypertension and hand-foot syndrome occurred in 84.21% and 73.68% of patients, respectively. A total of 15.8% of participants administered anlotinib experienced serious treatment-related adverse events.
Disclosure: For full disclosures of the study authors, visit oncologypro.esmo.org.